Navigation Links
Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer
Date:4/9/2013

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone , Ph.D., to the role of Chief Scientific Officer.

Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies.  Dr. Migone joins Igenica from Human Genome Sciences, where she held a variety of executive positions and most recently served as Vice President of Research.  In that role, she led scientific programs ranging from early discovery through Biologics License Applications, including belimumab and raxibacumab, two antibody programs that reached regulatory approval under her scientific leadership.  Prior to Human Genome Sciences, Dr. Migone held research positions at DNAX Research Institute, the National Heart, Lung and Blood Institute and National Institute of Allergy and Infectious Diseases.  Dr. Migone received a doctoral degree in Biological Sciences from the University of Pavia, Italy.

"Dr. Migone has a track record of leading and advancing biotherapeutics programs from discovery to successful product approval," said Mary Haak-Frendscho , Ph.D., Chief Executive Officer of Igenica.  "She brings an exceptional skillset and talent to Igenica at a time of great promise for Igenica's platform and first-in-class antibody-based therapeutic programs."

"Igenica has developed an integrated suite of differentiated technologies and capabilities supporting the discovery of novel cancer targets, antibodies and antibody-drug conjugates.  The Company is building a pipeline of next-generation cancer therapeutics that have significant potential to improve outcomes for cancer patients," said Dr. Migone.  "I am delighted to have this opportunity to contribute to Igenica's success."

About Igenica, Inc.

Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a forward-looking proteomics approach to discovering novel tumor antigens, iTAb, a functional in vivo antibody screening approach, and next generation antibody-drug conjugate technology.  Igenica's technology platforms drive innovative drug discovery and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel , Ph.D., The Column Group; John Diekman , Ph.D., 5AM Ventures; Mark A. Goldsmith , M.D., Ph.D., Third Rock Ventures; Carl Gordon , Ph.D., CFA, Orbimed Advisors; Mary Haak-Frendscho , Ph.D., Igenica, Inc.; Robert Schreiber , Ph.D., Igenica Founder and Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:
John K. Celebi , MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Igenica Closes $33 Million in Series C Funding
2. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):